Global VEGF-A Inhibitor Market Insights, Forecast to 2030

TABLE OF CONTENTS

1 Study Coverage

• 1.1 VEGF-A Inhibitor Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global VEGF-A Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
  • 1.2.2 Monoclonal Antibody
  • 1.2.3 Small Molecule Compound
• 1.3 Market by Application
  • 1.3.1 Global VEGF-A Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global VEGF-A Inhibitor Revenue Estimates and Forecasts 2019-2030
• 2.2 Global VEGF-A Inhibitor Revenue by Region
  • 2.2.1 Global VEGF-A Inhibitor Revenue by Region: 2019 VS 2023 VS 2030
  • 2.2.2 Global VEGF-A Inhibitor Revenue by Region (2019-2024)
  • 2.2.3 Global VEGF-A Inhibitor Revenue by Region (2025-2030)
  • 2.2.4 Global VEGF-A Inhibitor Revenue Market Share by Region (2019-2030)
• 2.3 Global VEGF-A Inhibitor Sales Estimates and Forecasts 2019-2030
• 2.4 Global VEGF-A Inhibitor Sales by Region
  • 2.4.1 Global VEGF-A Inhibitor Sales by Region: 2019 VS 2023 VS 2030
  • 2.4.2 Global VEGF-A Inhibitor Sales by Region (2019-2024)
  • 2.4.3 Global VEGF-A Inhibitor Sales by Region (2025-2030)
  • 2.4.4 Global VEGF-A Inhibitor Sales Market Share by Region (2019-2030)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufacturers

• 3.1 Global VEGF-A Inhibitor Sales by Manufacturers
  • 3.1.1 Global VEGF-A Inhibitor Sales by Manufacturers (2019-2024)
  • 3.1.2 Global VEGF-A Inhibitor Sales Market Share by Manufacturers (2019-2024)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of VEGF-A Inhibitor in 2023
• 3.2 Global VEGF-A Inhibitor Revenue by Manufacturers
  • 3.2.1 Global VEGF-A Inhibitor Revenue by Manufacturers (2019-2024)
  • 3.2.2 Global VEGF-A Inhibitor Revenue Market Share by Manufacturers (2019-2024)
  • 3.2.3 Global Top 10 and Top 5 Companies by VEGF-A Inhibitor Revenue in 2023
• 3.3 Global Key Players of VEGF-A Inhibitor, Industry Ranking, 2021 VS 2022
• 3.4 Global VEGF-A Inhibitor Sales Price by Manufacturers (2019-2024)
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global VEGF-A Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of VEGF-A Inhibitor, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of VEGF-A Inhibitor, Product Offered and Application
• 3.8 Global Key Manufacturers of VEGF-A Inhibitor, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global VEGF-A Inhibitor Sales by Type
  • 4.1.1 Global VEGF-A Inhibitor Historical Sales by Type (2019-2024)
  • 4.1.2 Global VEGF-A Inhibitor Forecasted Sales by Type (2025-2030)
  • 4.1.3 Global VEGF-A Inhibitor Sales Market Share by Type (2019-2030)
• 4.2 Global VEGF-A Inhibitor Revenue by Type
  • 4.2.1 Global VEGF-A Inhibitor Historical Revenue by Type (2019-2024)
  • 4.2.2 Global VEGF-A Inhibitor Forecasted Revenue by Type (2025-2030)
  • 4.2.3 Global VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)
• 4.3 Global VEGF-A Inhibitor Price by Type
  • 4.3.1 Global VEGF-A Inhibitor Price by Type (2019-2024)
  • 4.3.2 Global VEGF-A Inhibitor Price Forecast by Type (2025-2030)

5 Market Size by Application

• 5.1 Global VEGF-A Inhibitor Sales by Application
  • 5.1.1 Global VEGF-A Inhibitor Historical Sales by Application (2019-2024)
  • 5.1.2 Global VEGF-A Inhibitor Forecasted Sales by Application (2025-2030)
  • 5.1.3 Global VEGF-A Inhibitor Sales Market Share by Application (2019-2030)
• 5.2 Global VEGF-A Inhibitor Revenue by Application
  • 5.2.1 Global VEGF-A Inhibitor Historical Revenue by Application (2019-2024)
  • 5.2.2 Global VEGF-A Inhibitor Forecasted Revenue by Application (2025-2030)
  • 5.2.3 Global VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)
• 5.3 Global VEGF-A Inhibitor Price by Application
  • 5.3.1 Global VEGF-A Inhibitor Price by Application (2019-2024)
  • 5.3.2 Global VEGF-A Inhibitor Price Forecast by Application (2025-2030)

6 US & Canada

• 6.1 US & Canada VEGF-A Inhibitor Market Size by Type
  • 6.1.1 US & Canada VEGF-A Inhibitor Sales by Type (2019-2030)
  • 6.1.2 US & Canada VEGF-A Inhibitor Revenue by Type (2019-2030)
• 6.2 US & Canada VEGF-A Inhibitor Market Size by Application
  • 6.2.1 US & Canada VEGF-A Inhibitor Sales by Application (2019-2030)
  • 6.2.2 US & Canada VEGF-A Inhibitor Revenue by Application (2019-2030)
• 6.3 US & Canada VEGF-A Inhibitor Market Size by Country
  • 6.3.1 US & Canada VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030
  • 6.3.2 US & Canada VEGF-A Inhibitor Revenue by Country (2019-2030)
  • 6.3.3 US & Canada VEGF-A Inhibitor Sales by Country (2019-2030)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe VEGF-A Inhibitor Market Size by Type
  • 7.1.1 Europe VEGF-A Inhibitor Sales by Type (2019-2030)
  • 7.1.2 Europe VEGF-A Inhibitor Revenue by Type (2019-2030)
• 7.2 Europe VEGF-A Inhibitor Market Size by Application
  • 7.2.1 Europe VEGF-A Inhibitor Sales by Application (2019-2030)
  • 7.2.2 Europe VEGF-A Inhibitor Revenue by Application (2019-2030)
• 7.3 Europe VEGF-A Inhibitor Market Size by Country
  • 7.3.1 Europe VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030
  • 7.3.2 Europe VEGF-A Inhibitor Revenue by Country (2019-2030)
  • 7.3.3 Europe VEGF-A Inhibitor Sales by Country (2019-2030)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China VEGF-A Inhibitor Market Size by Type
  • 8.1.1 China VEGF-A Inhibitor Sales by Type (2019-2030)
  • 8.1.2 China VEGF-A Inhibitor Revenue by Type (2019-2030)
• 8.2 China VEGF-A Inhibitor Market Size by Application
  • 8.2.1 China VEGF-A Inhibitor Sales by Application (2019-2030)
  • 8.2.2 China VEGF-A Inhibitor Revenue by Application (2019-2030)

9 Asia (excluding China)

• 9.1 Asia VEGF-A Inhibitor Market Size by Type
  • 9.1.1 Asia VEGF-A Inhibitor Sales by Type (2019-2030)
  • 9.1.2 Asia VEGF-A Inhibitor Revenue by Type (2019-2030)
• 9.2 Asia VEGF-A Inhibitor Market Size by Application
  • 9.2.1 Asia VEGF-A Inhibitor Sales by Application (2019-2030)
  • 9.2.2 Asia VEGF-A Inhibitor Revenue by Application (2019-2030)
• 9.3 Asia VEGF-A Inhibitor Market Size by Region
  • 9.3.1 Asia VEGF-A Inhibitor Revenue by Region: 2019 VS 2023 VS 2030
  • 9.3.2 Asia VEGF-A Inhibitor Revenue by Region (2019-2030)
  • 9.3.3 Asia VEGF-A Inhibitor Sales by Region (2019-2030)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India
  • 9.3.9 Australia

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America VEGF-A Inhibitor Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Type (2019-2030)
  • 10.1.2 Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Type (2019-2030)
• 10.2 Middle East, Africa and Latin America VEGF-A Inhibitor Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Application (2019-2030)
  • 10.2.2 Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Application (2019-2030)
• 10.3 Middle East, Africa and Latin America VEGF-A Inhibitor Market Size by Country
  • 10.3.1 Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030
  • 10.3.2 Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Country (2019-2030)
  • 10.3.3 Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Country (2019-2030)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Corporate Profile

• 11.1 Novartis
  • 11.1.1 Novartis Company Information
  • 11.1.2 Novartis Overview
  • 11.1.3 Novartis VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.1.4 Novartis VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Novartis Recent Developments
• 11.2 Roche
  • 11.2.1 Roche Company Information
  • 11.2.2 Roche Overview
  • 11.2.3 Roche VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.2.4 Roche VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Roche Recent Developments
• 11.3 Pfizer
  • 11.3.1 Pfizer Company Information
  • 11.3.2 Pfizer Overview
  • 11.3.3 Pfizer VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.3.4 Pfizer VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Pfizer Recent Developments
• 11.4 Chengdu Kanghong Biotechnologies Co., Ltd.
  • 11.4.1 Chengdu Kanghong Biotechnologies Co., Ltd. Company Information
  • 11.4.2 Chengdu Kanghong Biotechnologies Co., Ltd. Overview
  • 11.4.3 Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.4.4 Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Chengdu Kanghong Biotechnologies Co., Ltd. Recent Developments
• 11.5 Innovent Biologics
  • 11.5.1 Innovent Biologics Company Information
  • 11.5.2 Innovent Biologics Overview
  • 11.5.3 Innovent Biologics VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.5.4 Innovent Biologics VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Innovent Biologics Recent Developments
• 11.6 Luye Pharma
  • 11.6.1 Luye Pharma Company Information
  • 11.6.2 Luye Pharma Overview
  • 11.6.3 Luye Pharma VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.6.4 Luye Pharma VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Luye Pharma Recent Developments
• 11.7 3SBio
  • 11.7.1 3SBio Company Information
  • 11.7.2 3SBio Overview
  • 11.7.3 3SBio VEGF-A Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.7.4 3SBio VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 3SBio Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 VEGF-A Inhibitor Industry Chain Analysis
• 12.2 VEGF-A Inhibitor Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 VEGF-A Inhibitor Production Mode & Process
• 12.4 VEGF-A Inhibitor Sales and Marketing
  • 12.4.1 VEGF-A Inhibitor Sales Channels
  • 12.4.2 VEGF-A Inhibitor Distributors
• 12.5 VEGF-A Inhibitor Customers

13 VEGF-A Inhibitor Market Dynamics

• 13.1 VEGF-A Inhibitor Industry Trends
• 13.2 VEGF-A Inhibitor Market Drivers
• 13.3 VEGF-A Inhibitor Market Challenges
• 13.4 VEGF-A Inhibitor Market Restraints

14 Key Findings in the Global VEGF-A Inhibitor Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

Table 1. Global VEGF-A Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Table 2. Major Manufacturers of Monoclonal Antibody

Table 3. Major Manufacturers of Small Molecule Compound

Table 4. Global VEGF-A Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Table 5. Global VEGF-A Inhibitor Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 6. Global VEGF-A Inhibitor Revenue by Region (2019-2024) & (US$ Million)

Table 7. Global VEGF-A Inhibitor Revenue by Region (2025-2030) & (US$ Million)

Table 8. Global VEGF-A Inhibitor Revenue Market Share by Region (2019-2024)

Table 9. Global VEGF-A Inhibitor Revenue Market Share by Region (2025-2030)

Table 10. Global VEGF-A Inhibitor Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)

Table 11. Global VEGF-A Inhibitor Sales by Region (2019-2024) & (K Units)

Table 12. Global VEGF-A Inhibitor Sales by Region (2025-2030) & (K Units)

Table 13. Global VEGF-A Inhibitor Sales Market Share by Region (2019-2024)

Table 14. Global VEGF-A Inhibitor Sales Market Share by Region (2025-2030)

Table 15. Global VEGF-A Inhibitor Sales by Manufacturers (2019-2024) & (K Units)

Table 16. Global VEGF-A Inhibitor Sales Share by Manufacturers (2019-2024)

Table 17. Global VEGF-A Inhibitor Revenue by Manufacturers (2019-2024) & (US$ Million)

Table 18. Global VEGF-A Inhibitor Revenue Market Share by Manufacturers (2019-2024)

Table 19. Global Key Players of VEGF-A Inhibitor, Industry Ranking, 2021 VS 2022 VS 2023

Table 20. VEGF-A Inhibitor Price by Manufacturers (2019-2024) & (US$/Unit)

Table 21. Global VEGF-A Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 22. Global VEGF-A Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF-A Inhibitor as of 2023)

Table 23. Global Key Manufacturers of VEGF-A Inhibitor, Manufacturing Base Distribution and Headquarters

Table 24. Global Key Manufacturers of VEGF-A Inhibitor, Product Offered and Application

Table 25. Global Key Manufacturers of VEGF-A Inhibitor, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global VEGF-A Inhibitor Sales by Type (2019-2024) & (K Units)

Table 28. Global VEGF-A Inhibitor Sales by Type (2025-2030) & (K Units)

Table 29. Global VEGF-A Inhibitor Sales Share by Type (2019-2024)

Table 30. Global VEGF-A Inhibitor Sales Share by Type (2025-2030)

Table 31. Global VEGF-A Inhibitor Revenue by Type (2019-2024) & (US$ Million)

Table 32. Global VEGF-A Inhibitor Revenue by Type (2025-2030) & (US$ Million)

Table 33. Global VEGF-A Inhibitor Revenue Share by Type (2019-2024)

Table 34. Global VEGF-A Inhibitor Revenue Share by Type (2025-2030)

Table 35. VEGF-A Inhibitor Price by Type (2019-2024) & (US$/Unit)

Table 36. Global VEGF-A Inhibitor Price Forecast by Type (2025-2030) & (US$/Unit)

Table 37. Global VEGF-A Inhibitor Sales by Application (2019-2024) & (K Units)

Table 38. Global VEGF-A Inhibitor Sales by Application (2025-2030) & (K Units)

Table 39. Global VEGF-A Inhibitor Sales Share by Application (2019-2024)

Table 40. Global VEGF-A Inhibitor Sales Share by Application (2025-2030)

Table 41. Global VEGF-A Inhibitor Revenue by Application (2019-2024) & (US$ Million)

Table 42. Global VEGF-A Inhibitor Revenue by Application (2025-2030) & (US$ Million)

Table 43. Global VEGF-A Inhibitor Revenue Share by Application (2019-2024)

Table 44. Global VEGF-A Inhibitor Revenue Share by Application (2025-2030)

Table 45. VEGF-A Inhibitor Price by Application (2019-2024) & (US$/Unit)

Table 46. Global VEGF-A Inhibitor Price Forecast by Application (2025-2030) & (US$/Unit)

Table 47. US & Canada VEGF-A Inhibitor Sales by Type (2019-2024) & (K Units)

Table 48. US & Canada VEGF-A Inhibitor Sales by Type (2025-2030) & (K Units)

Table 49. US & Canada VEGF-A Inhibitor Revenue by Type (2019-2024) & (US$ Million)

Table 50. US & Canada VEGF-A Inhibitor Revenue by Type (2025-2030) & (US$ Million)

Table 51. US & Canada VEGF-A Inhibitor Sales by Application (2019-2024) & (K Units)

Table 52. US & Canada VEGF-A Inhibitor Sales by Application (2025-2030) & (K Units)

Table 53. US & Canada VEGF-A Inhibitor Revenue by Application (2019-2024) & (US$ Million)

Table 54. US & Canada VEGF-A Inhibitor Revenue by Application (2025-2030) & (US$ Million)

Table 55. US & Canada VEGF-A Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 56. US & Canada VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 57. US & Canada VEGF-A Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 58. US & Canada VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 59. US & Canada VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 60. Europe VEGF-A Inhibitor Sales by Type (2019-2024) & (K Units)

Table 61. Europe VEGF-A Inhibitor Sales by Type (2025-2030) & (K Units)

Table 62. Europe VEGF-A Inhibitor Revenue by Type (2019-2024) & (US$ Million)

Table 63. Europe VEGF-A Inhibitor Revenue by Type (2025-2030) & (US$ Million)

Table 64. Europe VEGF-A Inhibitor Sales by Application (2019-2024) & (K Units)

Table 65. Europe VEGF-A Inhibitor Sales by Application (2025-2030) & (K Units)

Table 66. Europe VEGF-A Inhibitor Revenue by Application (2019-2024) & (US$ Million)

Table 67. Europe VEGF-A Inhibitor Revenue by Application (2025-2030) & (US$ Million)

Table 68. Europe VEGF-A Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 69. Europe VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 70. Europe VEGF-A Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 71. Europe VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 72. Europe VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 73. China VEGF-A Inhibitor Sales by Type (2019-2024) & (K Units)

Table 74. China VEGF-A Inhibitor Sales by Type (2025-2030) & (K Units)

Table 75. China VEGF-A Inhibitor Revenue by Type (2019-2024) & (US$ Million)

Table 76. China VEGF-A Inhibitor Revenue by Type (2025-2030) & (US$ Million)

Table 77. China VEGF-A Inhibitor Sales by Application (2019-2024) & (K Units)

Table 78. China VEGF-A Inhibitor Sales by Application (2025-2030) & (K Units)

Table 79. China VEGF-A Inhibitor Revenue by Application (2019-2024) & (US$ Million)

Table 80. China VEGF-A Inhibitor Revenue by Application (2025-2030) & (US$ Million)

Table 81. Asia VEGF-A Inhibitor Sales by Type (2019-2024) & (K Units)

Table 82. Asia VEGF-A Inhibitor Sales by Type (2025-2030) & (K Units)

Table 83. Asia VEGF-A Inhibitor Revenue by Type (2019-2024) & (US$ Million)

Table 84. Asia VEGF-A Inhibitor Revenue by Type (2025-2030) & (US$ Million)

Table 85. Asia VEGF-A Inhibitor Sales by Application (2019-2024) & (K Units)

Table 86. Asia VEGF-A Inhibitor Sales by Application (2025-2030) & (K Units)

Table 87. Asia VEGF-A Inhibitor Revenue by Application (2019-2024) & (US$ Million)

Table 88. Asia VEGF-A Inhibitor Revenue by Application (2025-2030) & (US$ Million)

Table 89. Asia VEGF-A Inhibitor Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 90. Asia VEGF-A Inhibitor Revenue by Region (2019-2024) & (US$ Million)

Table 91. Asia VEGF-A Inhibitor Revenue by Region (2025-2030) & (US$ Million)

Table 92. Asia VEGF-A Inhibitor Sales by Region (2019-2024) & (K Units)

Table 93. Asia VEGF-A Inhibitor Sales by Region (2025-2030) & (K Units)

Table 94. Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Type (2019-2024) & (K Units)

Table 95. Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Type (2025-2030) & (K Units)

Table 96. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Type (2019-2024) & (US$ Million)

Table 97. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Type (2025-2030) & (US$ Million)

Table 98. Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Application (2019-2024) & (K Units)

Table 99. Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Application (2025-2030) & (K Units)

Table 100. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Application (2019-2024) & (US$ Million)

Table 101. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Application (2025-2030) & (US$ Million)

Table 102. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 103. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 104. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 105. Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 106. Middle East, Africa and Latin America VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 107. Novartis Company Information

Table 108. Novartis Description and Major Businesses

Table 109. Novartis VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Novartis VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 111. Novartis Recent Developments

Table 112. Roche Company Information

Table 113. Roche Description and Major Businesses

Table 114. Roche VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. Roche VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 116. Roche Recent Developments

Table 117. Pfizer Company Information

Table 118. Pfizer Description and Major Businesses

Table 119. Pfizer VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 120. Pfizer VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 121. Pfizer Recent Developments

Table 122. Chengdu Kanghong Biotechnologies Co., Ltd. Company Information

Table 123. Chengdu Kanghong Biotechnologies Co., Ltd. Description and Major Businesses

Table 124. Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 125. Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 126. Chengdu Kanghong Biotechnologies Co., Ltd. Recent Developments

Table 127. Innovent Biologics Company Information

Table 128. Innovent Biologics Description and Major Businesses

Table 129. Innovent Biologics VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 130. Innovent Biologics VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 131. Innovent Biologics Recent Developments

Table 132. Luye Pharma Company Information

Table 133. Luye Pharma Description and Major Businesses

Table 134. Luye Pharma VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 135. Luye Pharma VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 136. Luye Pharma Recent Developments

Table 137. 3SBio Company Information

Table 138. 3SBio Description and Major Businesses

Table 139. 3SBio VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 140. 3SBio VEGF-A Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications

Table 141. 3SBio Recent Developments

Table 142. Key Raw Materials Lists

Table 143. Raw Materials Key Suppliers Lists

Table 144. VEGF-A Inhibitor Distributors List

Table 145. VEGF-A Inhibitor Customers List

Table 146. VEGF-A Inhibitor Market Trends

Table 147. VEGF-A Inhibitor Market Drivers

Table 148. VEGF-A Inhibitor Market Challenges

Table 149. VEGF-A Inhibitor Market Restraints

Table 150. Research Programs/Design for This Report

Table 151. Key Data Information from Secondary Sources

Table 152. Key Data Information from Primary Sources

List of Figures

Figure 1. VEGF-A Inhibitor Product Picture

Figure 2. Global VEGF-A Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global VEGF-A Inhibitor Market Share by Type: 2023 & 2030

Figure 4. Monoclonal Antibody Product Picture

Figure 5. Small Molecule Compound Product Picture

Figure 6. Global VEGF-A Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global VEGF-A Inhibitor Market Share by Application: 2023 & 2030

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Others

Figure 11. VEGF-A Inhibitor Report Years Considered

Figure 12. Global VEGF-A Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 14. Global VEGF-A Inhibitor Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Figure 15. Global VEGF-A Inhibitor Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 16. Global VEGF-A Inhibitor Revenue Market Share by Region (2019-2030)

Figure 17. Global VEGF-A Inhibitor Sales (2019-2030) & (K Units)

Figure 18. Global VEGF-A Inhibitor Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)

Figure 19. Global VEGF-A Inhibitor Sales Market Share by Region (2019-2030)

Figure 20. US & Canada VEGF-A Inhibitor Sales YoY (2019-2030) & (K Units)

Figure 21. US & Canada VEGF-A Inhibitor Revenue YoY (2019-2030) & (US$ Million)

Figure 22. Europe VEGF-A Inhibitor Sales YoY (2019-2030) & (K Units)

Figure 23. Europe VEGF-A Inhibitor Revenue YoY (2019-2030) & (US$ Million)

Figure 24. China VEGF-A Inhibitor Sales YoY (2019-2030) & (K Units)

Figure 25. China VEGF-A Inhibitor Revenue YoY (2019-2030) & (US$ Million)

Figure 26. Asia (excluding China) VEGF-A Inhibitor Sales YoY (2019-2030) & (K Units)

Figure 27. Asia (excluding China) VEGF-A Inhibitor Revenue YoY (2019-2030) & (US$ Million)

Figure 28. Middle East, Africa and Latin America VEGF-A Inhibitor Sales YoY (2019-2030) & (K Units)

Figure 29. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue YoY (2019-2030) & (US$ Million)

Figure 30. Global VEGF-A Inhibitor Sales Share by Manufacturers (2023)

Figure 31. The VEGF-A Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023

Figure 32. Global VEGF-A Inhibitor Revenue Share by Manufacturers (2023)

Figure 33. The Top 5 and 10 Largest Manufacturers of VEGF-A Inhibitor in the World: Market Share by VEGF-A Inhibitor Revenue in 2023

Figure 34. Global VEGF-A Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 35. Global VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

Figure 36. Global VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

Figure 37. Global VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

Figure 38. Global VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

Figure 39. US & Canada VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

Figure 40. US & Canada VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

Figure 41. US & Canada VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

Figure 42. US & Canada VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

Figure 43. US & Canada VEGF-A Inhibitor Revenue Share by Country (2019-2030)

Figure 44. US & Canada VEGF-A Inhibitor Sales Share by Country (2019-2030)

Figure 45. US VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 46. Canada VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 47. Europe VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

Figure 48. Europe VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

Figure 49. Europe VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

Figure 50. Europe VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

Figure 51. Europe VEGF-A Inhibitor Revenue Share by Country (2019-2030)

Figure 52. Europe VEGF-A Inhibitor Sales Share by Country (2019-2030)

Figure 53. Germany VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 54. France VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 55. U.K. VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 56. Italy VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 57. Russia VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 58. China VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

Figure 59. China VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

Figure 60. China VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

Figure 61. China VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

Figure 62. Asia VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

Figure 63. Asia VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

Figure 64. Asia VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

Figure 65. Asia VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

Figure 66. Asia VEGF-A Inhibitor Revenue Share by Region (2019-2030)

Figure 67. Asia VEGF-A Inhibitor Sales Share by Region (2019-2030)

Figure 68. Japan VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 69. South Korea VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 70. China Taiwan VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 71. Southeast Asia VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 72. India VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 73. Australia VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 74. Middle East, Africa and Latin America VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

Figure 75. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

Figure 76. Middle East, Africa and Latin America VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

Figure 77. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

Figure 78. Middle East, Africa and Latin America VEGF-A Inhibitor Revenue Share by Country (2019-2030)

Figure 79. Middle East, Africa and Latin America VEGF-A Inhibitor Sales Share by Country (2019-2030)

Figure 80. Brazil VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 81. Mexico VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 82. Turkey VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 83. Israel VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 84. GCC Countries VEGF-A Inhibitor Revenue (2019-2030) & (US$ Million)

Figure 85. VEGF-A Inhibitor Value Chain

Figure 86. VEGF-A Inhibitor Production Process

Figure 87. Channels of Distribution (Direct Vs Distribution)

Figure 88. Bottom-up and Top-down Approaches for This Report

Figure 89. Data Triangulation

Figure 90. Key Executives Interviewed